Últimas noticias sobre BMW (OTC:BMWKY) Bolsa

BMW is a premium passenger car and motorcycle original equipment manufacturer, home to the brands BMW, Mini Cooper, Rolls-Royce, and BMW Motorrad. BMW sold 2.8 million vehicles in 2023 (2.6 million being passenger cars). In terms of sales volumes, Asia and Europe are BMW's largest regions, contributing 39% and 38%, respectively. BMW's core competence is in the "affordable" luxury channel, with limited exposure to high-end priced vehicles.

Volkswagen Passat

Eurozone

BMWKY

MERCEDES-BENZ UNSP / ADR by Mercedes Benz Group AG

MBGYY

RNLSY

STLA

VLVOF

VWAGY

La Comisión Europea extiende a tres años el plazo para que los fabricantes cumplan sus objetivos de emisiones de CO₂.

La Comisión Europea flexibiliza los objetivos de emisiones de CO₂ para la industria automotriz

BAYERISCHE MTRNWRK U/ADR by Bayerische Motoren Werke AG

Bayerische Motoren Werke AG

UBS analyst Manav Gupta maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Buy and lowers the price target from $160 to $150.

News

Price Target

Analyst Ratings

UBS Maintains Buy on Valero Energy, Lowers Price Target to $150

UBS analyst Dennis Geiger maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Neutral and lowers the price target from $16 to $14.

UBS Maintains Neutral on Wendy's, Lowers Price Target to $14

Waste Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) reported mixed first-quarter financial results after the bell on Monday, and shares are moving lower. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b45054510/wm-announces-first-quarter-2025-earnings">of the report</a>.
<ul>
<li>Q1 Revenue: $6.02 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $6.12 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $1.67, versus estimates of $1.62</li>
</ul>
Total revenue was up 16.7% on a year-over-year basis. Waste Management said it generated $1.21 billion in cash from operations during the quarter, resulting in $475 million in free cash flow, in line with company expectations.
The company ended the first quarter with $216 million in cash and cash equivalents, down from $414 million at the end of the fourth quarter. 
&#8220;These solid&nbsp;first quarter&nbsp;results, as well as the strength and resiliency of our business model, give us confidence we are on pace to achieve our 2025&nbsp;outlook,&#8221; said&nbsp;Jim Fish, president and CEO of Waste Management.
Waste Management <a href="https://www.benzinga.com/pressreleases/25/01/b43324253/wm-announces-fourth-quarter-and-full-year-2024-earnings">previously guided</a> for full-year revenue of $25.5 billion to $25.8 billion. The company also forecasted for full-year free cash flow of approximately $2.68 billion to $2.78 billion when it reported fourth-quarter results.
Waste Management executives will further discuss the quarter on a conference call with investors and analysts at 10 a.m. ET Tuesday morning.
WM Price Action: <a href="http://benzinga.com/quote/WM">Waste Management shares</a> were down 1.78% at $225.01 after-hours at publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">NXP Semiconductors Reports Q1 Earnings: &#8216;Very Uncertain&#8217; Operating Environment Tied To Tariffs, CEO Transition, Shares Fall</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45054717/transocean-stock-climbs-after-mixed-q1-results-eps-miss-revenue-beats">Transocean Stock Climbs After Mixed Q1 Results: EPS Miss, Revenue Beats</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45053893/amkor-technology-shares-climb-after-q1-revenue-beats-q2-revenue-guidance-above-estimates">Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/paulmatthew">BCFC</a>/Shutterstock.

Earnings

After-Hours Center

Movers

Waste Management Stock Dips On Mixed Q1 Results, Company Says It's 'On Pace' To Achieve 2025 Outlook

UBS analyst Dennis Geiger maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Neutral and lowers the price target from $300 to $255.

WING

UBS Maintains Neutral on Wingstop, Lowers Price Target to $255

UBS analyst Timothy Arcuri maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and lowers the price target from $130 to $92.

UBS Maintains Buy on Micron Technology, Lowers Price Target to $92

UBS analyst Spiro Dounis maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Buy and lowers the price target from $144 to $140.

UBS Maintains Buy on Phillips 66, Lowers Price Target to $140

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) sees Q2 sales of $2.171 billion-$2.238 billion vs $2.18 billion analyst estimate.

Guidance

NOV Sees Q2 Sales $2.171B-$2.238B vs $2.18B Est

UBS analyst Thomas Wadewitz maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $422 to $305.

SAIA

UBS Maintains Buy on Saia, Lowers Price Target to $305

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.25 per share. This is a 7.41 percent decrease over earnings of $0.27 per share from the same period last year. The company reported $33.55 million in sales this quarter. This is a 4.99 percent decrease over sales of $35.31 million the same period last year.

National Research Q1 EPS $0.25 Down From $0.27 YoY, Revenue $33.55M Down From $35.31M YoY

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.26 by 26.92 percent. This is a 36.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $2.10 billion which met the analyst consensus estimate. This is a 2.41 percent decrease over sales of $2.15 billion the same period last year.

Earnings Misses

NOV Q1 EPS $0.19 Misses $0.26 Estimate, Sales $2.10B Inline

UBS analyst Dennis Geiger maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and lowers the price target from $105 to $90.

SBUX

UBS Maintains Neutral on Starbucks, Lowers Price Target to $90

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 15.4% on an annualized basis producing an average annual return of 29.66%. Currently, Krystal Biotech has a market capitalization of $4.89 billion. 
Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 years ago, it would be worth $359.67 today based on a price of $169.73 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745876711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

KRYS

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

UBS analyst Lloyd Walmsley maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Buy and lowers the price target from $5960 to $5557.

BKNG

UBS Maintains Buy on Booking Holdings, Lowers Price Target to $5557

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q2 GAAP EPS of $0.35-$0.48 vs $0.51 analyst estimate..

Teradyne Sees Q2 GAAP EPS $0.35-$0.48 vs $0.51 Est

UBS analyst Jay Sole maintains Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) with a Neutral and lowers the price target from $37 to $32.

UBS Maintains Neutral on Carter's, Lowers Price Target to $32

<a href="https://www.bloomberg.com/news/articles/2025-04-28/boeing-removed-from-credit-watch-by-s-p-in-turnaround-boost?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-04-28/boeing-removed-from-credit-watch-by-s-p-in-turnaround-boost?embedded-checkout=true</a>

General

'Boeing Removed From Credit Watch by S&P in Turnaround Boost'- Bloomberg

UBS analyst Stephen Ju maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and lowers the price target from $194 to $170.

EXPE

UBS Maintains Neutral on Expedia Group, Lowers Price Target to $170

German American Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GABC#NASDAQ">GABC</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.66 by 19.7 percent. This is a 27.42 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $81.41 million which beat the analyst consensus estimate of $79.56 million by 2.33 percent. This is a 33.87 percent increase over sales of $60.82 million the same period last year.

Earnings Beats

GABC

German American Bancorp Q1 Adj. EPS $0.79 Beats $0.66 Estimate, Sales $81.41M Beat $79.56M Estimate

UBS analyst Brian Meredith maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Buy and lowers the price target from $145 to $140.

GSHD

UBS Maintains Buy on Goosehead Insurance, Lowers Price Target to $140

UBS analyst Ashwani Verma maintains Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and lowers the price target from $55 to $48.

Comments

BMW

Noticias

Últimas noticias sobre BMW (OTC:BMWKY) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL